Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291

Warning: Missing argument 2 for wpdb::prepare(), called in /home4/bquality/public_html/wp-content/plugins/membership/membershipincludes/classes/membershippublic.php on line 2303 and defined in /home4/bquality/public_html/wp-includes/wp-db.php on line 1291
Amgen Scientists Publish New Tool to Aid Selection of rProtein Leads | BioQuality.biz

Productivity and Quality of Recombinant Proteins Produced by Stable CHO Cell Clones can be Predicted by Transient Expression in HEK Cells (click the large title above to see the whole post)

 

Mol Biotechnol. 2012 Aug 23. [Epub ahead of print], Diepenbruck C, Klinger M, Urbig T, Baeuerle P, Neef R., Amgen Research (Munich) GmbH, Staffelseestr. 2, 81477, Munich, Germany.

 

Bullet-point Overview:

  • The authors describe an approach that allows prediction of the productivity and quality of recombinant proteins by stable producer cell clones with the help of transient transfection studies
  • As examples, they presented results from three distinct bispecific T cell engager (BiTE(®))-a new class of single-chain antibody-based therapeutics showing very promising results in the treatment of cancer
  • They found that BiTE(®) titers of transiently transfected HEK cells showed a striking correlation with titers of selected stable CHO cell clones
  • In addition, the percentage of the monomeric BiTE(®) fraction in cell culture supernatants correlated well between transiently expressing HEK and stably expressing CHO cell clones
  • According to the authors, this validates the use of transient transfection studies for the selection of biopharmaceutical lead candidates with desired pharmaceutical properties

 

To see the Abstract, and a link to obtain this paper: http://www.ncbi.nlm.nih.gov/pubmed/22915356

 

Subscribe to BioQuality and stay on top of the important Regulatory and Technical literature (see the link to subscribe on the Member’s Page or our Home Page). The topics we cover include:

  • Adverse Event Monitoring and Reporting
  • Analytical Methods for Characterization and Control
  • Anti-drug Antibodies and Unwanted Immunogenicity
  • At the Cutting Edge
  • Basic Science Relevant to Biopharma and Biologics
  • Bioanalytical Methods and Issues
  • Biological Potency, Activity, and other Biological Assays
  • Biomarkers
  • Biosimilars, Follow-on Biologics, FOPPs, Biobetters, etc.
  • Carbohydrate/Glycan/Oligosaccharide/Polysaccharide Characterization and Analysis
  • Cellular Therapies and Regenerative Medicine
  • Clinical Issues
  • Container/Closure Issues
  • Data Analysis, Mathematical Models and Statistics
  • Development Costs
  • Development Issues, Concerns, Strategies, etc.
  • Deviations, Handling and Reporting
  • Discovery Research
  • Distribution Issues
  • European Regulations and Regulatory Perspective
  • Excipient Analysis and Control
  • Formulation and Delivery
  • Gene and other Nucleic Acid Therapy
  • General Business Issues
  • GMP Compliance, General
  • Good Distribution Practice
  • Host Cell Proteins
  • Laboratory Issues
  • Manufacturing and Production Issues
  • Method Qualification and Validation
  • Microbial Analysis and Control
  • Molecular and Personalized Medicine
  • Nucleic Acids
  • Particulate Analysis
  • Personalized and Molecular Medicine
  • Preclinical Issues
  • Process Monitoring, and Control, Process Analytical Technology (PAT)
  • Process Development
  • Product Development, Pre-clinical and Clinical
  • Protein, Glycoprotein, Peptide, and Other Bio-molecule Structure/Function
  • Proteins, Glycoproteins, Peptides, Antibodies and Other Biomolecules: Characterization, Analysis, and Control
  • Quality by Design (QbD)
  • Raw Material Analysis and Control
  • Regenerative Medicine
  • Regulations, General Considerations
  • Regulatory Agencies
  • Regulatory Submissions, Review, Reporting, etc.
  • Reference Standard Qualification and Verification
  • Risk Analysis and Management
  • Safety and Efficacy Issues
  • Separation Science
  • Stability Issues
  • Surveillance and Pharmacovigilance
  • Vaccine Development, Testing, Control, Production, Delivery, Stability
  • Validation

 

Don’t see your favorite Biopharma/Biologics topic? Send me an email: biotech1ster@gmail.com and I will add it to my searches (if it is consonant with our ed policy, of course)

Comments

Post a comment

You must be logged in to post a comment.

BioQuality.com. Copyright © 2015. All rights reserved.
Turning Information into Practical Knowledge